ATE395359T1 - Peptid zur appetitzügelung, dessen zusammensetzungen und verwendung - Google Patents

Peptid zur appetitzügelung, dessen zusammensetzungen und verwendung

Info

Publication number
ATE395359T1
ATE395359T1 AT01122701T AT01122701T ATE395359T1 AT E395359 T1 ATE395359 T1 AT E395359T1 AT 01122701 T AT01122701 T AT 01122701T AT 01122701 T AT01122701 T AT 01122701T AT E395359 T1 ATE395359 T1 AT E395359T1
Authority
AT
Austria
Prior art keywords
peptide
compositions
appetite suppression
appetite
absent
Prior art date
Application number
AT01122701T
Other languages
German (de)
English (en)
Inventor
Lars Thim
Birgitte Wulff
Martin Edward Judge
Ole Dragsbaek Madsen
Jens Juul Holst
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26063575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE395359(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE395359T1 publication Critical patent/ATE395359T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT01122701T 1996-03-01 1997-02-27 Peptid zur appetitzügelung, dessen zusammensetzungen und verwendung ATE395359T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK23096 1996-03-01
DK23196 1996-03-01

Publications (1)

Publication Number Publication Date
ATE395359T1 true ATE395359T1 (de) 2008-05-15

Family

ID=26063575

Family Applications (3)

Application Number Title Priority Date Filing Date
AT01122701T ATE395359T1 (de) 1996-03-01 1997-02-27 Peptid zur appetitzügelung, dessen zusammensetzungen und verwendung
AT97905000T ATE227737T1 (de) 1996-03-01 1997-02-27 Gebrauch einer pharmazeutischen zusammensetzung, enthaltend ein appetitzügelndes peptid
AT08103786T ATE505485T1 (de) 1996-03-01 1997-02-27 Appetithemmendes peptid, zusammensetzung und verwendung

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT97905000T ATE227737T1 (de) 1996-03-01 1997-02-27 Gebrauch einer pharmazeutischen zusammensetzung, enthaltend ein appetitzügelndes peptid
AT08103786T ATE505485T1 (de) 1996-03-01 1997-02-27 Appetithemmendes peptid, zusammensetzung und verwendung

Country Status (22)

Country Link
EP (4) EP1231218B1 (2)
JP (1) JP4064460B2 (2)
KR (1) KR100611130B1 (2)
CN (1) CN1112367C (2)
AT (3) ATE395359T1 (2)
AU (1) AU710818B2 (2)
BR (1) BR9707807A (2)
CA (1) CA2246733C (2)
CY (2) CY2619B2 (2)
CZ (1) CZ297338B6 (2)
DE (3) DE69738695D1 (2)
DK (2) DK1975177T3 (2)
ES (3) ES2364705T3 (2)
FR (1) FR13C0009I2 (2)
HU (1) HU229234B1 (2)
IL (1) IL125805A0 (2)
NO (2) NO323043B1 (2)
PL (1) PL187095B1 (2)
PT (1) PT1975177E (2)
RU (1) RU2197261C2 (2)
UA (1) UA70283C2 (2)
WO (1) WO1997031943A1 (2)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
DK1975177T3 (da) * 1996-03-01 2011-07-25 Novo Nordisk As Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
ES2351661T3 (es) 1996-04-12 2011-02-09 1149336 Ontario Inc. Péptido-2 análogo al glucagón.
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69737916T2 (de) * 1996-11-12 2008-04-03 Novo Nordisk A/S Verwendung von GLP-1 Peptiden
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
DE59811840D1 (de) * 1997-09-12 2004-09-23 Pharis Biotec Gmbh Zusammensetzung zur therapie von diabetes mellitus und fettsucht
WO1999029336A1 (en) * 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
AU2610599A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2002504527A (ja) * 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
WO1999043707A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999047161A1 (en) * 1998-03-19 1999-09-23 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
DE60134251D1 (de) * 2000-09-18 2008-07-10 Sanos Bioscience As Verwendung von glp-2-peptiden
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
DE60136958D1 (de) 2000-12-01 2009-01-22 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004035624A2 (en) 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
ATE502665T1 (de) 2003-02-04 2011-04-15 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
EP2298337B1 (en) 2003-12-09 2017-02-22 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
CA2552043A1 (en) 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
KR101040415B1 (ko) * 2004-04-15 2011-06-09 알케르메스,인코포레이티드 중합체 기재 지속적 방출 방법
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
RU2262945C1 (ru) * 2004-04-29 2005-10-27 Закрытое акционерное общество "Научно-производственное предприятие "Тринита" Способ снижения массы тела в эксперименте на животных
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CA2607150C (en) † 2005-05-04 2014-08-05 Bjarne Due Larsen Glucagon-like-peptide-2 (glp-2) analogues
RS51319B (sr) 2005-09-22 2010-12-31 Biocompatibles Uk Limited GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
JP5048773B2 (ja) 2006-08-09 2012-10-17 インターシア セラピューティクス，インコーポレイティド 浸透圧式デリバリーシステム及びピストンアセンブリー
CA2669806C (en) 2006-11-08 2018-10-02 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
CN101854947A (zh) * 2007-08-16 2010-10-06 圣文森特医院悉尼有限公司 用于调节巨噬细胞抑制因子(mic-1)活性的药剂和方法
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR101576126B1 (ko) 2014-12-29 2015-12-11 부경대학교 산학협력단 αＡＬ１４ 펩타이드를 유효성분으로 함유하는 신규 비만 예방 및 치료용 약학적 조성물
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
BR112019010624A2 (pt) 2016-12-09 2019-10-22 Zealand Pharma As agonistas duplos de glp-1/glp-2 acilados e composição
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
KR102504200B1 (ko) 2017-06-16 2023-02-28 질랜드 파마 에이/에스 글루카곤-유사-펩티드-2 (glp-2) 유사체의 투여를 위한 용량요법
AU2020268087A1 (en) * 2019-05-06 2021-11-25 The University Of Sydney Methods for the fractionation of proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
DE3382547D1 (de) 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
WO1984004330A1 (en) 1983-04-22 1984-11-08 Amgen Secretion of exogenous polypeptides from yeast
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4632925A (en) * 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
WO1987002670A1 (en) 1985-10-25 1987-05-07 Mackay Vivian L Method of using bar1 for secreting foreign proteins
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
WO1989001029A1 (en) 1987-07-24 1989-02-09 Cetus Corporation Airlift insect cell culture
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
SU1697823A1 (ru) * 1988-08-01 1991-12-15 Киевский государственный институт усовершенствования врачей Способ лечени алиментарно-конституционального ожирени
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
AU4647889A (en) 1988-11-18 1990-06-12 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
DK1975177T3 (da) * 1996-03-01 2011-07-25 Novo Nordisk As Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf

Also Published As

Publication number Publication date
NO984005D0 (no) 1998-08-31
AU710818B2 (en) 1999-09-30
EP0891378A1 (en) 1999-01-20
ES2364705T3 (es) 2011-09-12
DK1975177T3 (da) 2011-07-25
NO2013006I2 (2) 2013-03-12
CA2246733C (en) 2010-07-20
RU2197261C2 (ru) 2003-01-27
CY2619B2 (2) 2013-03-13
NO2013006I1 (no) 2013-04-02
CY2013008I2 (el) 2015-08-05
EP2295453A3 (en) 2011-03-30
WO1997031943A1 (en) 1997-09-04
CA2246733A1 (en) 1997-09-04
IL125805A0 (en) 1999-04-11
JP4064460B2 (ja) 2008-03-19
EP1975177B1 (en) 2011-04-13
NO984005L (no) 1998-08-31
FR13C0009I1 (2) 2013-03-22
DE69740176D1 (de) 2011-05-26
PT1975177E (pt) 2011-07-26
ATE505485T1 (de) 2011-04-15
EP1231218A3 (en) 2002-10-30
AU1871597A (en) 1997-09-16
EP1231218B1 (en) 2008-05-14
DE69717092D1 (de) 2002-12-19
KR19990087439A (ko) 1999-12-27
DE69717092T2 (de) 2003-07-24
CZ297338B6 (cs) 2006-11-15
NO323043B1 (no) 2006-12-27
EP2295453A2 (en) 2011-03-16
ATE227737T1 (de) 2002-11-15
BR9707807A (pt) 1999-07-27
PL187095B1 (pl) 2004-05-31
DE69738695D1 (de) 2008-06-26
PL328732A1 (en) 1999-02-15
HU229234B1 (en) 2013-09-30
ES2187756T3 (es) 2003-06-16
FR13C0009I2 (fr) 2013-08-16
CN1112367C (zh) 2003-06-25
CN1215405A (zh) 1999-04-28
EP1975177A1 (en) 2008-10-01
DK0891378T3 (da) 2003-01-06
HUP9902670A3 (en) 2000-02-28
EP0891378B1 (en) 2002-11-13
ES2306685T3 (es) 2008-11-16
UA70283C2 (en) 2004-10-15
CY2013008I1 (el) 2015-08-05
KR100611130B1 (ko) 2006-11-30
CZ273698A3 (cs) 1998-12-16
JP2000505460A (ja) 2000-05-09
EP1231218A2 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
ATE395359T1 (de) Peptid zur appetitzügelung, dessen zusammensetzungen und verwendung
DK1171465T3 (da) Analoger til gastroinhibitorisk peptid og deres anvendelse til behandling af diabetes
NO992557L (no) Bruk av GLP-1-analoger og derivater administrert perifert i regulering av fedme
DK1094834T3 (da) Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf
ATE366584T1 (de) Verwendung von glp-1 peptiden
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
SG160205A1 (en) Modified polypeptide
DK0759772T3 (da) Tri-, tetra-, penta- og polypeptider og deres terapeutiske anvendelse som antidepressiva
ATE218064T1 (de) Immunogene tlp-zusammensetzung
WO2002036628A3 (en) New multimeric interferon beta polypeptides
ATE305478T1 (de) Topoisomerase-ii inhibitoren
MX9601655A (es) Proteinas (ob) obesas recombinantes.
TH26711A (th) " สิ่งที่คล้ายกันของปัจจัยหลั่งฮอโมนของการเจริญเติบโต "

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties